Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials
Autor: | Ruizhe Chen, Sanjib Basu, Jeffrey P Meyers, Qian Shi |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Statistical Methods in Medical Research. 31:1819-1844 |
ISSN: | 1477-0334 0962-2802 |
DOI: | 10.1177/09622802221102621 |
Popis: | The restricted mean survival time measure has gained a lot of interests for designing and analyzing oncology trials with time-to-event endpoints due to its intuitive clinical interpretation and potentially high statistical power. In the non-inferiority trial literature, restricted mean survival time has been used as an alternative measure for reanalyzing a completed trial, which was originally designed and analyzed based on traditional proportional hazard model. However, the reanalysis procedure requires a conversion from the non-inferiority margin measured in hazard ratio to a non-inferiority margin measured by restricted mean survival time difference. An existing conversion method assumes a Weibull distribution for the population survival time of the historical active control group under the proportional hazard assumption using data from a single trial. In this article, we develop a methodology for non-inferiority margin conversion when data from multiple historical active control studies are available, and introduce a Kaplan-Meier estimator-based method for the non-inferiority margin conversion to relax the parametric assumption. We report extensive simulation studies to examine the performances of proposed methods under the Weibull data generative models and a piecewise-exponential data generative model that mimic the tumor recurrence and survival characteristics of advanced colon cancer. This work is motivated to achieve non-inferiority margin conversion, using historical patient-level data from a large colon cancer clinical database, to reanalyze an internationally collaborated non-inferiority study that evaluates 6-month versus 3-month duration of adjuvant chemotherapy in stage III colon cancer patients. |
Databáze: | OpenAIRE |
Externí odkaz: |